Margins of biologics stood at 38% in Q1 as compared to 33% in the preceding quarter
Separation of Pfizer's off-patent business would be a tax-free spin-off
Being highly regulated, brands are wary about being too adventurous online
Price erosion has been in excess of 15 per cent last year and will perhaps be at similar levels this year due to sales channel consolidation, says Kaul
The cardiac segment is the most hit, with a loss pegged at Rs 250 crore.
About Rs 12,000 cr of the roughly Rs 1 lakh cr turnover of market would be impacted